Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Medtronic
Harvard Business School
Merck

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,858,118

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,858,118 protect, and when does it expire?

Patent 7,858,118 protects CONZIP and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 7,858,118
Title:Extended release composition containing Tramadol
Abstract:An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (T.sub.max) of greater than 10 hours, and peak Tramadol plasma concentration (C.sub.max) which are less than three times the plasma concentration obtained 24 hours after administration (C.sub.24h) of a single dose of the composition.
Inventor(s): Deboeck; Arthur M. (Gurabo, PR), Vanderbist; Francis (Meise, BE), Sereno; Antonio (Melsbroeck, BE)
Assignee: Galephar Pharmaceutical Research, Inc. (Juncos, PR)
Application Number:10/119,939
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 7,858,118

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370-001 May 7, 2010 RX Yes Yes   Start Trial   Start Trial Y USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN   Start Trial
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370-002 May 7, 2010 RX Yes No   Start Trial   Start Trial Y USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN   Start Trial
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370-003 May 7, 2010 RX Yes No   Start Trial   Start Trial Y USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
AstraZeneca
Moodys
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.